-
Sector Analysis
mRNA Vaccines in Infectious Diseases Market Outlook and Trends by Opportunities, Challenges, Unmet Needs, and Competitive Landscape
mRNA Vaccines in Infectious Diseases Market Report Overview The first mRNA vaccines for COVID-19 gained authorization for use in December 2020. These vaccines have been proven highly successful clinically and commercially, dominating the COVID-19 vaccine market. Furthermore, the success of the COVID-19 mRNA vaccines has renewed interest in mRNA vaccines for a variety of other infectious diseases such as influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), Mpox, herpes, Zika virus, and Lyme disease. The report provides an assessment of the...
-
Product Insights
NewInfluenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H3N2 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H3N2 infections are caused by variant H3N2 virus, which is a strain of influenza. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age and chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics. The Influenza A...
-
Product Insights
NewAvian Influenza – Drugs In Development, 2024
Empower your strategies with our Avian Influenza – Drugs In Development, 2024 report and make more profitable business decisions. Avian influenza, commonly referred to as bird flu, is a viral infection that primarily affects birds, especially poultry such as chickens and turkeys. Various strains of avian influenza viruses exist, some of which can cause severe illness in birds and, in certain cases, pose a risk to human health. Avian influenza viruses belong to the influenza A virus family and are classified...
-
Product Insights
NewMiddle East Respiratory Syndrome (MERS) – Drugs In Development, 2024
Empower your strategies with our Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2024 report and make more profitable business decisions. Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting, and diarrhea. Pneumonia is common, and organs damage can occur to the kidneys or other organs. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications. The...
-
Product Insights
NewInfluenzavirus B Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus B Infections – Drugs In Development, 2024 report and make more profitable business decisions. Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite, and weakness. Treatment includes antivirals, analgesics, and antipyretics medications. The Influenzavirus B Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Influenzavirus B...
-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Lymphoma Drug Details: Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fidrisertib in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fidrisertib in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fidrisertib in Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) Drug...